Suppr超能文献

优化非酒精性脂肪性肝病纤维化评分、纤维化-4 评分和肝脏硬度测量的应用,以识别进展性纤维化患者。

Optimizing Use of Nonalcoholic Fatty Liver Disease Fibrosis Score, Fibrosis-4 Score, and Liver Stiffness Measurement to Identify Patients With Advanced Fibrosis.

机构信息

Gastroenterology and Hepatology Unit, Department of Medicine, University of Malaya, Kuala Lumpur, Malaysia.

Division of Gastroenterology, Department of Medicine, Chulalongkorn University, Bangkok, Thailand.

出版信息

Clin Gastroenterol Hepatol. 2019 Nov;17(12):2570-2580.e37. doi: 10.1016/j.cgh.2019.03.006. Epub 2019 Mar 12.

Abstract

BACKGROUND & AIMS: Measuring liver stiffness only in patients with indeterminate or high nonalcoholic fatty liver disease (NAFLD) fibrosis scores (called a 2-step approach) was reported to reduce indeterminate or discordant results while maintaining the accuracy to identify patients with advanced fibrosis. We aimed to validate this approach using data collected from the Gut and Obesity in Asia Workgroup.

METHODS

We performed a retrospective analysis of data from 759 patients with biopsy-proven NAFLD (24% with advanced fibrosis), seen at 10 centers in 9 countries in Asia, from 2006 through 2018. By using liver biopsies as the reference standard, we calculated percentages of misclassifications and indeterminate or discordant results from assessments made based on fibrosis scores (NAFLD fibrosis score [NFS] or Fibrosis-4 score) and liver stiffness measurements (LSMs), alone or in combination. The analysis was repeated using randomly selected subgroups with a different prevalence of advanced fibrosis (histologic fibrosis stage ≥F3).

RESULTS

In groups in which 3.7% and 10% of patients had advanced fibrosis, a 2-step approach (using the NFS followed by LSM only for patients with indeterminate or high NFS) and using a gray zone of 10 to 15 kPa for LSM, produced indeterminate or discordant results for 6.9% of patients and misclassified 2.7% of patients; only 25.6% of patients required LSM. In the group in which 10% of patients had advanced fibrosis, the same approach produced indeterminate or discordant results for 7.9% of patients and misclassified 6.6% of patients; only 27.4% of patients required LSM. In groups in which 24% and 50% of patients had advanced fibrosis, using LSM ≥10 kPa alone for the diagnosis of advanced fibrosis had the highest accuracy and misclassified 18.1% and 18.3% of patients, respectively. These results were similar when the Fibrosis-4 score was used in place of NFS.

CONCLUSIONS

In a retrospective analysis, we found that a 2-step approach using fibrosis scores followed by LSM most accurately detects advanced fibrosis in populations with a low prevalence of advanced fibrosis. However, LSM ≥10 kPa identifies patients with advanced fibrosis with the highest level of accuracy in populations with a high prevalence of advanced fibrosis.

摘要

背景与目的

有研究报道,对非酒精性脂肪性肝病(NAFLD)纤维化评分不确定或高分的患者仅进行肝硬度检测(两步法),可减少不确定或不一致的结果,同时保持识别晚期纤维化患者的准确性。我们旨在使用亚洲肠道和肥胖工作组收集的数据对此方法进行验证。

方法

我们对 2006 年至 2018 年间在亚洲 9 个国家的 10 个中心就诊的 759 例经活检证实的 NAFLD 患者(24%有晚期纤维化)的数据进行了回顾性分析。我们以肝活检为参考标准,计算了纤维化评分(NAFLD 纤维化评分[NFS]或纤维化-4 评分)和肝硬度测量(LSM)单独或组合评估时的错误分类率和不确定或不一致结果的百分比。我们使用不同晚期纤维化患病率(组织学纤维化分期≥F3)的随机亚组重复了该分析。

结果

在纤维化评分不确定或高分的患者比例分别为 3.7%和 10%的组中,两步法(先用 NFS 评分,再对不确定或高分患者仅行 LSM 检查)和 LSM 灰区为 10~15 kPa,导致 6.9%的患者结果不确定或不一致,2.7%的患者被错误分类;只有 25.6%的患者需要进行 LSM 检查。在纤维化评分不确定或高分的患者比例为 10%的组中,同样的方法导致 7.9%的患者结果不确定或不一致,6.6%的患者被错误分类;只有 27.4%的患者需要进行 LSM 检查。在纤维化评分不确定或高分的患者比例分别为 24%和 50%的组中,单独使用 LSM≥10 kPa 诊断晚期纤维化的准确性最高,分别错误分类 18.1%和 18.3%的患者。当使用 Fibrosis-4 评分代替 NFS 时,结果相似。

结论

在回顾性分析中,我们发现,在低晚期纤维化患病率人群中,使用纤维化评分两步法后再行 LSM 检测可最准确地检测出晚期纤维化。然而,在晚期纤维化患病率较高的人群中,LSM≥10 kPa 对识别晚期纤维化患者具有最高的准确性。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验